British Drugmaker GSK Unveils $30 Billion Investment In Their U.S. Operations
British drugmaker GSK has announced a major $30 billion investment into its U.S. operations over the next five years, coinciding with President Trump’s visit to the UK. The move, aimed at strengthening research, development, and manufacturing, will see a $1.2 billion biologics factory built in Pennsylvania for cancer and respiratory medicines, along with upgrades across five existing American sites using AI and digital tools.
The company says the investment will “bridge R&D and manufacturing across both the U.S. and UK,” reinforcing both nations’ roles in life sciences. Prime Minister Keir Starmer called it a “powerful example” of UK-U.S. collaboration, while U.S. Commerce Secretary Howard Lutnick said the deal would create “tens of thousands of American jobs.” GSK CEO Emma Walmsley added, “We are proud to be part of both.”
The announcement follows growing pressure from the Trump administration on drugmakers to shift production stateside, including threats of steep import tariffs. As a result, several pharma giants like Merck and AstraZeneca have scaled back or canceled UK projects. Despite this trend, GSK confirmed it will still invest over £1.5 billion annually into R&D in the UK.
